AKLI

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Baillie GiffordInvestor $-2.0M ExitQ3 2024 $2.0M -- --
Baillie GiffordInvestor $-2.0M ExitQ3 2024 $2.0M -- --
Jim SimonsRenaissance Technologies $-55.2K ExitQ3 2024 $55k -- --
Jim SimonsRenaissance Technologies $-55.2K ExitQ3 2024 $55k -- --
Ken GriffinCitadel Advisors $-7.1K ExitQ3 2024 $7.1k -- --
Ken GriffinCitadel Advisors $-7.1K ExitQ3 2024 $7.1k -- --

Trade AKLI

About Akili, Inc.

Akili, Inc. is a digital medicine enterprise focused on developing innovative digital therapies for individuals experiencing cognitive impairments. Its flagship product, EndeavorRx, stands out as a unique video game-based treatment that necessitates a physician's prescription and is specifically engineered to directly target and improve cognitive functioning. This company operates from its headquarters in Boston, Massachusetts.

CEO: Matthew Franklin
IPO Date: Jun 30, 2021

Market Data

Open: $0.43
High: $0.4331
Low: $0.43
Volume: 236.5K
52W High: $1.25
52W Low: $0.1912

Valuation

Market Cap: $34M
Enterprise Value: $-26M

Financials

Free Cash Flow: $-58M
Revenue: $1.7M
Net Income: $-59M
Cash: $75M
Debt: $15M

Events

EarningsAug 8

actual -0.18